Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test

Shun Ishido; Nobuharu Tamaki; Kento Inada; Jun Itakura; Yuka Takahashi; Naoki Uchihara; Keito Suzuki; Yuki Tanaka; Haruka Miyamoto; Michiko Yamada; Hiroaki Matsumoto; Tsubasa Nobusawa; Taisei Keitoku; Kenta Takaura; Shohei Tanaka; Chiaki Maeyashiki; Yutaka Yasui; Kaoru Tsuchiya; Hiroyuki Nakanishi; Masayuki Kurosaki; Namiki Izumi

doi:10.1002/ccr3.7664

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test

Clin Case Rep. 2023 Jul 5;11(7):e7664. doi: 10.1002/ccr3.7664. eCollection 2023 Jul.

Authors

Shun Ishido¹, Nobuharu Tamaki¹, Kento Inada¹, Jun Itakura¹, Yuka Takahashi¹, Naoki Uchihara¹, Keito Suzuki¹, Yuki Tanaka¹, Haruka Miyamoto¹, Michiko Yamada¹, Hiroaki Matsumoto¹, Tsubasa Nobusawa¹, Taisei Keitoku¹, Kenta Takaura¹, Shohei Tanaka¹, Chiaki Maeyashiki¹, Yutaka Yasui¹, Kaoru Tsuchiya¹, Hiroyuki Nakanishi¹, Masayuki Kurosaki¹, Namiki Izumi¹

Affiliation

¹ Department of Gastroenterology and Hepatology Musashino Red Cross Hospital Tokyo Japan.

Abstract

The liquid CGP was useful for detecting FGFR2 fusion and the patient experienced typical side effects (nail disorders, hyperphosphatemia, and taste disorders) of pemigatinib that required treatment.

Keywords: comprehensive genomic profiling; fibroblast growth factor receptor 2; intrahepatic cholangiocarcinoma; pemigatinib.

Publication types

Case Reports